Cambrooke Therapeutics Introducing Tylactin Complete Bars For Tyrosinemia (TYR)

AYER, Mass.--(BUSINESS WIRE)--Cambrooke Therapeutics Inc., a leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the launch of Tylactin™ COMPLETE Bars, a nutritionally complete medical food, available in a convenient portable format, for the dietary management of Tyrosinemia (TYR).

“He does not want to finish it, and I have had to watch him carefully. This new Tylactin COMPLETE Bar is a joy for him, and I never have to worry about him finishing it. I am so thankful to Cambrooke for inventing such a wonderful product for my son.”

Tylactin with GMP is made from a natural whole protein derived from whey called glycomacropeptide (GMP). Cambrooke Therapeutics was the first company to provide individuals with Tyrosinemia natural whole protein medical foods—Tylactin RTD and Tylactin RESTORE. Now, Tylactin COMPLETE Bars provides an additional option for individuals struggling to consume their formula or those people who need a compact, on-the-go, and great-tasting formula.

Each Tylactin COMPLETE Bar package contains three segments, each with 5g protein equivalents. This novel bar format is available in a delicious chocolate/peanut butter flavor. Tylactin COMPLETE Bars are an ideal addition to any TYR diet program for use at school, as a snack, or any time on-the-go convenience is desired.

“My son struggled to take all his formula every day,” says Maria C., mother to a TYR child. “He does not want to finish it, and I have had to watch him carefully. This new Tylactin COMPLETE Bar is a joy for him, and I never have to worry about him finishing it. I am so thankful to Cambrooke for inventing such a wonderful product for my son.”

About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooke.com.